Bimmer E Claessen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3211157/publications.pdf

Version: 2024-02-01

209	6,971	66343	69250
papers	citations	42 h-index	77 g-index

260	260	260	6606
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In-Stent Restenosis in the Drug-Eluting Stent Era. Journal of the American College of Cardiology, 2010, 56, 1897-1907.	2.8	663
2	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 654-664.	2.9	329
3	Percutaneous Intervention for ConcurrentÂChronic Total Occlusions inÂPatients WithÂSTEMI. Journal of the American College of Cardiology, 2016, 68, 1622-1632.	2.8	300
4	Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2011, 4, 952-961.	2.9	260
5	Prognostic Impact of Staged Versus â€œOne-Timeâ€•Multivessel Percutaneous Intervention in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 704-711.	2.8	236
6	Evaluation of the Effect of a Concurrent Chronic Total Occlusion on Long-Term Mortality and Left Ventricular Function in Patients After Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2009, 2, 1128-1134.	2.9	208
7	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. European Heart Journal, 2012, 33, 768-775.	2.2	206
8	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ, The, 2013, 347, f6530-f6530.	6.0	194
9	ST-segment elevation myocardial infarction. Nature Reviews Disease Primers, 2019, 5, 39.	30.5	179
10	Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1081-1092.	2.9	159
11	Impact of In-Hospital Major Bleeding on Late Clinical Outcomes After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 1750-1756.	2.8	127
12	Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. International Journal of Cardiology, 2015, 187, 90-96.	1.7	126
13	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). European Heart Journal, 2020, 41, 3715-3728.	2.2	121
14	Impact of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump on Prognostically Important Clinical Outcomes in Patients Undergoing High-Risk Percutaneous Coronary Intervention (from the PROTECT II Randomized Trial). American Journal of Cardiology, 2014, 113, 222-228.	1.6	116
15	Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 1209-1215.	2.9	115
16	Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions. Circulation: Cardiovascular Interventions, 2009, 2, 339-347.	3.9	109
17	Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 1011-1019.	2.9	107
18	Impact of Intravascular Ultrasound Imaging on Early and Late Clinical Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 974-981.	2.9	106

#	Article	IF	Citations
19	Effect of Multivessel Coronary Disease With or Without Concurrent Chronic Total Occlusion on One-Year Mortality in Patients Treated With Primary Percutaneous Coronary Intervention for Cardiogenic Shock. American Journal of Cardiology, 2010, 105, 955-959.	1.6	105
20	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2012, 5, 1097-1105.	2.9	101
21	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. Journal of the American College of Cardiology, 2020, 75, 2664-2678.	2.8	93
22	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal, 2022, 43, e17-e25.	2.2	92
23	The impact of multivessel disease with and without a coâ€existing chronic total occlusion on shortâ€• and longâ€term mortality in STâ€elevation myocardial infarction patients with and without cardiogenic shock. European Journal of Heart Failure, 2013, 15, 425-432.	7.1	90
24	Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. European Heart Journal, 2018, 39, 4101-4108.	2.2	89
25	A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the TreatmentÂof Any In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 275-283.	2.9	88
26	Coronary Calcification and Long-TermÂOutcomes According to Drug-Eluting Stent Generation. JACC: Cardiovascular Interventions, 2020, 13, 1417-1428.	2.9	77
27	Residual Inflammatory Risk in PatientsÂWith Low LDL Cholesterol LevelsÂUndergoing Percutaneous CoronaryÂIntervention. Journal of the American College of Cardiology, 2019, 73, 2401-2409.	2.8	69
28	Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. Heart, 2010, 96, 843-847.	2.9	60
29	Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Trials, 2010, 11, 89.	1.6	58
30	Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. American Heart Journal, 2011, 161, 391-396.	2.7	58
31	Right ventricular dysfunction is an independent predictor for mortality in STâ€elevation myocardial infarction patients presenting with cardiogenic shock on admission. European Journal of Heart Failure, 2010, 12, 276-282.	7.1	57
32	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. European Heart Journal, 2021, 42, 339-351.	2.2	57
33	Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. Heart, 2018, 104, 1432-1438.	2.9	55
34	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e007411.	3.9	55
35	Predictive Value of Plasma Glucose Level on Admission for Short and Long Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2012, 109, 53-59.	1.6	53
36	Prevalence and impact of a chronic total occlusion in a non-infarct-related artery on long-term mortality in diabetic patients with ST elevation myocardial infarction. Heart, 2010, 96, 1968-1972.	2.9	52

#	Article	IF	Citations
37	Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital. Journal of the American College of Cardiology, 2012, 59, 1752-1759.	2.8	51
38	Plaque Composition by Intravascular Ultrasound and Distal Embolization After Percutaneous Coronary Intervention. JACC: Cardiovascular Imaging, 2012, 5, S111-S118.	5.3	50
39	CTCA for detection of significant coronary artery disease in routine TAVI work-up. Netherlands Heart Journal, 2018, 26, 591-599.	0.8	50
40	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 2309-2316.	2.8	49
41	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. Journal of Thrombosis and Thrombolysis, 2014, 37, 155-164.	2.1	49
42	Efficacy of the RADPAD Protection Drape in Reducing Operatorsâ€™ Radiation Exposure in the Catheterization Laboratory. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	48
43	Impact of target vessel on longâ€term survival after percutaneous coronary intervention for chronic total occlusions. Catheterization and Cardiovascular Interventions, 2013, 82, 76-82.	1.7	46
44	Culprit Vesselâ€“Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	44
45	Radial versus femoral access for coronary interventions: An updated systematic review and metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2021, 97, 1387-1396.	1.7	42
46	Long-Term Clinical Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2011, 108, 924-931.	1.6	41
47	B-type Natriuretic Peptide and Risk of Contrast-Induced Acute Kidney Injury in Acute ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2012, 5, 813-820.	3.9	41
48	Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial. Journal of Cardiovascular Magnetic Resonance, 2017, 19, 53.	3.3	41
49	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 225-235.	3.0	40
50	Focus on maximal miniaturisation of transradial coronary access materials and techniques by the Slender Club Japan and Europe: an overview and classification. EuroIntervention, 2015, 10, 1178-1186.	3.2	40
51	Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. EuroIntervention, 2013, 9, 220-227.	3.2	39
52	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVOâ€3 randomized trial. Catheterization and Cardiovascular Interventions, 2019, 93, 1374-1381.	1.7	35
53	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. Nature Reviews Cardiology, 2022, 19, 195-208.	13.7	34
54	Contemporary overview and clinical perspectives of chronic total occlusions. Nature Reviews Cardiology, 2014, 11, 458-469.	13.7	33

#	Article	IF	Citations
55	Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 1231-1238.	2.9	32
56	Impact of Collateral Circulation on Survival in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention With a Concomitant Chronic Total Occlusion. JACC: Cardiovascular Interventions, 2017, 10, 906-914.	2.9	30
57	Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1009-1015.	1.0	30
58	Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	28
59	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. Circulation, 2020, 141, 891-901.	1.6	28
60	Angioscopic and Virtual Histology Intravascular Ultrasound Characteristics of Culprit Lesion Morphology Underlying Coronary Artery Thrombosis. American Journal of Cardiology, 2011, 107, 1285-1290.	1.6	27
61	Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. EuroIntervention, 2014, 10, 90-96.	3.2	26
62	Long-term safety and sustained left ventricular recovery: long-term results of percutaneous left ventricular support with Impella LP2.5 in ST-elevation myocardial infarction. EuroIntervention, 2011, 6, 860-865.	3.2	26
63	Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 113, 229-235.	1.6	25
64	Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. EuroIntervention, 2013, 8, 1033-1039.	3.2	25
65	Gender differences in long-term clinical outcomes after percutaneous coronary intervention of chronic total occlusions. Journal of Invasive Cardiology, 2012, 24, 484-8.	0.4	25
66	Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?. Netherlands Heart Journal, 2010, 18, 451-453.	0.8	24
67	Mitral regurgitation is an independent predictor of 1-year mortality in ST-elevation myocardial infarction patients presenting in cardiogenic shock on admission.. Acute Cardiac Care, 2010, 12, 51-57.	0.2	24
68	Longâ€term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (â‰¥75 Years). Catheterization and Cardiovascular Interventions, 2013, 82, 85-92.	1.7	24
69	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. Journal of the American Heart Association, 2020, 9, e018897.	3.7	23
70	Prognostic Value of Free Plasma Homocysteine Levels in Patients Hospitalized With Acute Coronary Syndrome. American Journal of Cardiology, 2008, 102, 135-139.	1.6	22
71	Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute STâ€segment elevation myocardial infarction: Results of the <scp>HORIZONSâ€AMI</scp> trial. Catheterization and Cardiovascular Interventions, 2015, 85, 335-342.	1.7	22
72	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WINâ€TAVI registry. Catheterization and Cardiovascular Interventions, 2019, 93, 1124-1131.	1.7	22

#	Article	IF	Citations
73	Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clinical Research in Cardiology, 2019, 108, 643-650.	3.3	21
74	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008226.	3.9	21
75	Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2018, 118, 1997-2005.	3.4	19
76	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). American Journal of Cardiology, 2019, 123, 1494-1500.	1.6	19
77	Considerations for Optimal Device Selection in Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2021, 6, 102-112.	6.1	19
78	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2018, 122, 1909-1916.	1.6	18
79	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007133.	3.9	17
80	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 2432-2447.	2.8	17
81	Adjunctive thrombus aspiration versus conventional percutaneous coronary intervention in STâ€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2013, 81, 922-929.	1.7	16
82	Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease. Expert Review of Cardiovascular Therapy, 2018, 16, 825-835.	1.5	16
83	The prevalence, predictors and outcomes of guidelineâ€directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 2019, 93, E112-E119.	1.7	16
84	Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: The SPIRIT II Trial. Circulation: Cardiovascular Interventions, 2009, 2, 339-347.	3.9	15
85	The Doppler flow wire in acute myocardial infarction. Heart, 2010, 96, 631-635.	2.9	14
86	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2012, 34, 165-179.	2.1	14
87	Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. Journal of Clinical Medicine, 2022, 11, 1361.	2.4	14
88	Evaluation of the Impact of a Chronic Total Coronary Occlusion on Ventricular Arrhythmias and Longâ€Term Mortality in Patients With Ischemic Cardiomyopathy and an Implantable CardioverterâEDefibrillator (the eCTOpyâ€inâ€ICD Study). Journal of the American Heart Association, 2018, 7, .	3.7	13
89	Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion. European Radiology, 2020, 30, 600-608.	4.5	13
90	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WINâ€TAVI) registry. Catheterization and Cardiovascular Interventions, 2020, 96, 198-207.	1.7	13

#	Article	IF	Citations
91	Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: AÂweighted meta-analysis of seven randomised controlled trials including 5577 patients. Netherlands Heart Journal, 2017, 25, 429-438.	0.8	12
92	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. JACC: Cardiovascular Interventions, 2019, 12, 983-992.	2.9	12
93	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. International Journal of Cardiology, 2019, 275, 31-35.	1.7	12
94	Sexâ€Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patientâ€Level Pooled Analysis From 4 Postapproval Studies. Journal of the American Heart Association, 2020, 9, e014611.	3.7	12
95	Current status of the Xience V^{Â®}everolimus-eluting coronary stent system. Expert Review of Cardiovascular Therapy, 2010, 8, 1363-1374.	1.5	11
96	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Thrombosis and Haemostasis, 2015, 114, 933-944.	3.4	11
97	Impact of collateralisation to a concomitant chronic total occlusion in patients with ST-elevation myocardial infarction: a subanalysis of the EXPLORE randomised controlled trial. Open Heart, 2018, 5, e000810.	2.3	11
98	Impact of insulin treated and nonâ€insulinâ€treated diabetes compared to patients without diabetes on 1â€year outcomes following contemporary PCI. Catheterization and Cardiovascular Interventions, 2020, 96, 298-308.	1.7	11
99	A sex paradox in clinical outcomes following complex percutaneous coronary intervention. International Journal of Cardiology, 2021, 329, 67-73.	1.7	11
100	Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems. Current Pharmaceutical Design, 2010, 16, 4012-4024.	1.9	10
101	Long-term outcomes of aÂCaucasian cohort presenting with acute coronary syndrome and/or out-of-hospital cardiac arrest caused by coronary spasm. Netherlands Heart Journal, 2018, 26, 26-33.	0.8	10
102	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. International Journal of Cardiology, 2019, 297, 22-29.	1.7	10
103	Smallâ€vessel PCI outcomes in men, women, and minorities following platinum chromium everolimusâ€eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Postâ€Approval studies. Catheterization and Cardiovascular Interventions, 2019, 94, 82-90.	1.7	10
104	The link between anemia and adverse outcomes in patients with acute coronary syndrome. Expert Review of Cardiovascular Therapy, 2019, 17, 151-159.	1.5	10
105	DEtection of ProxImal Coronary stenosis in the work-up for Transcatheter aortic valve implantation using CTA (from the DEPICT CTA collaboration). European Radiology, 2022, 32, 143-151.	4.5	10
106	Identification and treatment of the vulnerable coronary plaque. Reviews in Cardiovascular Medicine, 2022, 23, 1.	1.4	10
107	Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention â€" From the PROTECT II randomized trial. International Journal of Cardiology, 2015, 189, 272-278.	1.7	9
108	Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. Journal of Thrombosis and Thrombolysis, 2016, 41, 441-451.	2.1	9

#	Article	IF	Citations
109	Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1941-1948.	1.6	9
110	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2019, 123, 709-716.	1.6	9
111	Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly. Netherlands Heart Journal, 2015, 23, 477-482.	0.8	8
112	A SMILE and a Frown. Journal of the American College of Cardiology, 2016, 67, 273-274.	2.8	8
113	Meta-Analysis Comparing Complete or Culprit Only Revascularization in Patients With Multivessel Disease Presenting With Cardiogenic Shock. American Journal of Cardiology, 2018, 122, 1661-1669.	1.6	8
114	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. International Journal of Cardiology, 2019, 287, 59-61.	1.7	8
115	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WINâ€TAVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, E704-E715.	1.7	8
116	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 2022, 53, 20-29.	2.1	8
117	The impact of the location of a chronic total occlusion in a non-infarct-related artery on long-term mortality in ST-elevation myocardial infarction patients. EuroIntervention, 2016, 12, 423-430.	3.2	8
118	Fractional Flow Reserve-Guided Percutaneous Coronary Intervention: Does Coronary Pressure Never Lie?. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 294.	0.9	7
119	Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1788-1795.	1.6	7
120	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. American Heart Journal, 2019, 207, 10-18.	2.7	7
121	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 76, 435-450.	2.8	7
122	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. Clinical Research in Cardiology, 2021, 110, 649-657.	3.3	7
123	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. Catheterization and Cardiovascular Interventions, 2021, 98, E908-E917.	1.7	7
124	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2013, 35, 200-208.	2.1	6
125	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. International Journal of Cardiology, 2018, 263, 24-28.	1.7	6
126	Paravalvular Leak. Journal of the American College of Cardiology, 2018, 72, 2149-2151.	2.8	6

#	Article	IF	Citations
127	The effect of revascularization of a chronic total coronary occlusion on electrocardiographic variables. A sub-study of the EXPLORE trial. Journal of Electrocardiology, 2018, 51, 906-912.	0.9	6
128	Value of the SYNTAX Score in ST-Elevation Myocardial Infarction Patients With a Concomitant Chronic Total Coronary Occlusion(from the EXPLORE Trial). American Journal of Cardiology, 2019, 123, 1035-1043.	1.6	6
129	Impact of stent diameter on outcomes following percutaneous coronary intervention with secondâ€generation drugâ€eluting stents: Results from a large singleâ€center registry. Catheterization and Cardiovascular Interventions, 2020, 96, 558-564.	1.7	6
130	Safety and efficacy of the bioabsorbable polymer everolimusâ€eluting stent versus durable polymer drugâ€eluting stents in highâ€risk patients undergoing PCI : TWILIGHTâ€SYNERGY. Catheterization and Cardiovascular Interventions, 2021, 97, 63-71.	1.7	6
131	Current State and Future Perspectives of Artificial Intelligence for Automated Coronary Angiography Imaging Analysis in Patients with Ischemic Heart Disease. Current Cardiology Reports, 2022, 24, 365-376.	2.9	6
132	Physiology-guided myocardial revascularisation in complex multivessel coronary artery disease: beyond the 2014 ESC/EACTS guidelines on myocardial revascularisation. Open Heart, 2015, 2, e000308.	2.3	5
133	Impact of Chronic Total Occlusion Location on LV Function in ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2017, 69, 2347-2348.	2.8	5
134	Revascularization Strategies in Cardiogenic Shock Patients With MVD. Journal of the American College of Cardiology, 2018, 71, 857-859.	2.8	5
135	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. Journal of Thrombosis and Thrombolysis, 2019, 48, 42-51.	2.1	5
136	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary interventionâ€"Results from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 2020, 95, 885-892.	1.7	5
137	Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clinical Research in Cardiology, 2020, 109, 725-734.	3.3	5
138	Two-Year Safety and Effectiveness of Sirolimus-Eluting Stents (from a Prospective Registry). American Journal of Cardiology, 2011, 107, 528-534.	1.6	4
139	Cardiology fellows-in-training are exposed to relatively high levels of radiation in the cath lab compared with staff interventional cardiologistsâ€"insights from the RECAP trial. Netherlands Heart Journal, 2019, 27, 330-333.	0.8	4
140	Paclitaxelâ€eluting balloon versus everolimusâ€eluting stent in patients with diabetes mellitus and inâ€stent restenosis: Insights from the randomized DARE trial. Catheterization and Cardiovascular Interventions, 2019, 93, 216-221.	1.7	4
141	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. Journal of Thrombosis and Thrombolysis, 2022, 53, 380-389.	2.1	4
142	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. American Journal of Cardiology, 2022, 168, 47-54.	1.6	4
143	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120009495.	3.9	4
144	Exercise testing after chronic total coronary occlusion revascularization in patients with STEMI and a concurrent CTO: A subanalysis of the EXPLOREâ€trial. Catheterization and Cardiovascular Interventions, 2019, 94, 536-545.	1.7	3

#	Article	IF	Citations
145	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. International Journal of Cardiology, 2021, 322, 65-69.	1.7	3
146	Acute myocardial infarction, chronic total occlusion, and cardiogenic shock: the ultimate triple threat. EuroIntervention, 2018, 14, e252-e254.	3.2	3
147	A Dutch perspective on the ESC/EACTS guidelines on myocardial revascularisation. Netherlands Heart Journal, 2015, 23, 290-291.	0.8	2
148	TCT-387 Collateral quality decay several days after primary PCI: a novel observation from the EXPLORE trial.. Journal of the American College of Cardiology, 2017, 70, B159.	2.8	2
149	Hope for the best, prepare for the worst: How to manage coronary perforations. Catheterization and Cardiovascular Interventions, 2019, 93, E255-E256.	1.7	2
150	Use of prasugrel and clinical outcomes in Africanâ€American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2019, 94, 53-60.	1.7	2
151	FFR in the Setting of ACS. JACC: Cardiovascular Interventions, 2020, 13, 1904-1906.	2.9	2
152	Implications of Kidney Disease in the Cardiac Patient. Interventional Cardiology Clinics, 2020, 9, 265-278.	0.4	2
153	Predictors and outcomes of procedural failure of percutaneous coronary intervention of a chronic total occlusionâ€"A subanalysis of the EXPLORE trial. Catheterization and Cardiovascular Interventions, 2021, 97, 1176-1183.	1.7	2
154	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. Journal of Thrombosis and Thrombolysis, 2021, 52, 419-428.	2.1	2
155	Impact of sex on longâ€term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2021, 98, E494-E500.	1.7	2
156	Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. Catheterization and Cardiovascular Interventions, 2021, 98, E785-E795.	1.7	2
157	The Role of Percutaneous Haemodynamic Support in High-risk Percutaneous Coronary Intervention and Cardiogenic Shock. Interventional Cardiology Review, 2015, 10, 39.	1.6	2
158	Healing of a coronary artery dissection detected by intravascular ultrasound and optical coherence tomography. EuroIntervention, 2011, 7, 288-289.	3.2	2
159	Relation of Multivessel Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction to Outcome and/or Non-Infarct Artery Intervention of a Chronic Total Occlusion. American Journal of Cardiology, 2010, 105, 902-903.	1.6	1
160	Thrombus Aspiration in Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 643-644.	2.9	1
161	Meta-analyses and randomized trials investigating percutaneous coronary intervention of chronic total occlusions: what is left to explore?. Journal of Thoracic Disease, 2016, 8, E1100-E1102.	1.4	1
162	Patient delay in women with STEMI: Time to raise awareness. International Journal of Cardiology, 2018, 262, 30-31.	1.7	1

#	Article	IF	Citations
163	TCT-539 Clinical outcomes in high bleeding risk patients undergoing complex PCI with the Xience everolimus eluting stent: a patient-level pooled analysis from four Xience post-approval trials. Journal of the American College of Cardiology, 2018, 72, B217.	2.8	1
164	TCT-835 Validation of PARIS Risk Scores in Patients Treated With Everolimus-Eluting Stents for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial. Journal of the American College of Cardiology, 2018, 72, B333.	2.8	1
165	Go With the Flow When Instantaneous Wave-Free Ratio-Fractional Flow Reserve Discordance Occurs. JACC: Cardiovascular Interventions, 2018, 11, 2435-2436.	2.9	1
166	The quest for the optimal treatment for inâ€stent restenosis. Catheterization and Cardiovascular Interventions, 2018, 92, 300-301.	1.7	1
167	600.09 In-Hospital Outcomes of Patients with Bicuspid Aortic Valve Undergoing Transcatheter Aortic Valve Replacement: A Nationwide Analysis. JACC: Cardiovascular Interventions, 2019, 12, S45.	2.9	1
168	Leave nothing behind: Promising results for coronary drugâ€coated balloons in clinical practice. Catheterization and Cardiovascular Interventions, 2019, 93, 189-190.	1.7	1
169	Comparison of Age (<75 Years Vs â‰¥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study). American Journal of Cardiology, 2020, 125, 685-693.	1.6	1
170	TCT CONNECT-307 Long-Term Outcomes After Coronary Intervention With Drug Eluting Stents for Unprotected Left Main Coronary Artery Stenosis According to Diabetes Mellitus Status. Journal of the American College of Cardiology, 2020, 76, B132-B133.	2.8	1
171	Stent Technology Reaches Maturity?. JACC: Cardiovascular Interventions, 2020, 13, 2879-2881.	2.9	1
172	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVOâ€3 trial. Catheterization and Cardiovascular Interventions, 2020, 96, E688-E694.	1.7	1
173	Cangrelor Use in Routine Practice: A Two-Center Experience. Journal of Clinical Medicine, 2021, 10, 2829.	2.4	1
174	Recovery of right ventricular function and strain in patients with ST-segment elevation myocardial infarction and concurrent chronic total occlusion. International Journal of Cardiovascular Imaging, 2022, 38, 631-641.	1.5	1
175	Evaluating the need for a practical risk score to predict major bleeding in acute coronary syndromes. Interventional Cardiology, 2010, 2, 757-759.	0.0	0
176	One-year clinical outcome after treatment of bare-metal stent in-stent restenosis with the paclitaxel-eluting stent in an unselected cohort. International Journal of Cardiology, 2010, 145, 608-609.	1.7	0
177	TCT-446 Long-Term Clinical Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions in Elderly Patients (â‰¥75 years): Five-Year Outcomes from a 1,791 Patient Multi-National Registry. Journal of the American College of Cardiology, 2012, 60, B128.	2.8	0
178	Balance of Ischemia and Bleeding in Selecting an Antithrombotic Regimen. Interventional Cardiology Clinics, 2013, 2, 515-525.	0.4	0
179	Vasoactive and Antiarrhythmic Drugs During Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2013, 2, 665-670.	0.4	0
180	TCT-196 Meta-Analysis on the impact of percutaneous coronary intervention of Chronic Total Occlusions on Long-term Mortality. Journal of the American College of Cardiology, 2014, 64, B58.	2.8	0

#	Article	IF	Citations
181	Does the Association Between a High Body Mass Index and Hospital Mortality Weigh â€œHeavilyâ€•on the Association Between a Low Body Mass Index and Hospital Mortality?. Critical Care Medicine, 2014, 42, e79.	0.9	0
182	Collateral Quality Decay Several Days After Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 511-512.	2.9	0
183	Reply. JACC: Cardiovascular Interventions, 2018, 11, 506-507.	2.9	0
184	Recurrent myocardial infarction in a 47â€yearâ€old woman with a mechanical mitral valve prosthesis: Atherosclerosis, embolism, or spasm?. Catheterization and Cardiovascular Interventions, 2018, 91, 267-270.	1.7	0
185	TCT-736 Prevalence and Impact of Bleeding Determinants on Risks for out-of-hospital bleeding and coronary thrombosis in patients undergoing percutaneous coronary intervention: Results from a large single-center PCI Registry. Journal of the American College of Cardiology, 2018, 72, B295.	2.8	0
186	How to manage chronic total occlusions in the setting of acute myocardial infarction complicated by cardiogenic shock?. Catheterization and Cardiovascular Interventions, 2018, 92, 464-465.	1.7	0
187	Letter by Kikkert et al Regarding Article, â€œEffect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)â€•. Circulation, 2018, 138, 214-215.	1.6	0
188	RESIDUAL INFLAMMATORY RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. Journal of the American College of Cardiology, 2019, 73, 1357.	2.8	0
189	IMPACT OF GENDER AND RACE ON OUTCOMES AFTER COMPLEX PERCUTANEOUS CORONARY INTERVENTION WITH THE PLATINUM-CHROMIUM EVEROLIMUS-ELUTING STENT: A POOLED ANALYSIS OF THE PLATINUM DIVERSITY AND PROMUS ELEMENT PLUS POST-APPROVAL STUDIES. Journal of the American College of Cardiology, 2019, 73, 1358.	2.8	0
190	TCT-307 Vascular Closure Device Use After PCI for Left Main Disease: Analysis From the EXCEL Trial. Journal of the American College of Cardiology, 2019, 74, B305.	2.8	0
191	TCT-315 White Blood Cell Count and 4-Year Clinical Outcomes After Left Main Coronary Artery Revascularization: Insights From the EXCEL Trial. Journal of the American College of Cardiology, 2019, 74, B313.	2.8	0
192	TCT-662 Patients Who Do Not Receive Drug-Eluting Stent for In-Stent Restenosis: Characteristics and Outcomes. Journal of the American College of Cardiology, 2019, 74, B650.	2.8	0
193	TCT-686 The Impact of Coronary Artery Disease and Pre-Procedural PCI on the Short- and Long-Term Mortality After TAVR. Journal of the American College of Cardiology, 2019, 74, B673.	2.8	0
194	TCT-214 Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Chronic Total Coronary Occlusions: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of the American College of Cardiology, 2019, 74, B213.	2.8	0
195	Minding the Microcirculation. Circulation: Cardiovascular Interventions, 2019, 12, e008312.	3.9	0
196	Complementary role of cardiac computed tomography angiography in the diagnosis of prosthetic aortic valve endocarditis and septic coronary embolism - a case report. Journal of Radiology Case Reports, 2019, 13, 9-14.	0.4	0
197	IMPACT OF PERCUTANEOUS CORONARY INTERVENTION COMPLEXITY IN REAL-WORLD PRACTICE. Journal of the American College of Cardiology, 2019, 73, 1274.	2.8	0
198	TCT CONNECT-162 Predictors of Adverse Events in Patients Undergoing Cardiac Surgery Within 1 Year of PCI. Journal of the American College of Cardiology, 2020, 76, B69-B70.	2.8	0

#	Article	IF	Citations
199	TCT CONNECT-305 Impact of Lesion Location on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents for Unprotected Left Main Coronary Artery Stenosis. Journal of the American College of Cardiology, 2020, 76, B131-B132.	2.8	0
200	Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2020, 137, 1-6.	1.6	0
201	IMPACT OF INCOMPLETE REVASCULARIZATION OF THE LEFT ANTERIOR DESCENDING ARTERY VERSUS OTHER CORONARY ARTERIES AFTER PCI: INSIGHTS FROM THE RIVER-PCI TRIAL. Journal of the American College of Cardiology, 2020, 75, 192.	2.8	0
202	TCT CONNECT-379 Adverse Outcomes in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 76, B163.	2.8	0
203	White blood cell count and clinical outcomes after left main coronary artery revascularization. Coronary Artery Disease, 2021, Publish Ahead of Print, 45-51.	0.7	0
204	Stents farmacolÃ³gicos eluidores de everolimus na prÃ¡tica no mundo real. Revista Brasileira De Cardiologia Invasiva, 2011, 19, 351-352.	0.1	0
205	Chronic Total Occlusions. , 2014, , 1-18.		0
206	Rationale and Technique for Percutaneous Coronary Intervention of Chronic Total Occlusions. , 2015, , 2281-2296.		0
207	Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents. American Journal of Cardiology, 2022, , .	1.6	0
208	The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve Replacement. Journal of Invasive Cardiology, 2021, 33, E823-E832.	0.4	0
209	Residual Inflammatory Risk After Percutaneous Coronary Intervention. JACC Asia, 2022, , .	1.5	0